Surviving metastatic non-small cell lung cancer (mNSCLC): The lived experience and supportive care needs of patients (pts) receiving immunotherapy (IT) or targeted therapy (TT)

Background: IT and TT have improved survival for many pts with mNSCLC. However, the lived experience of these pts is under-studied. We conducted a single centre, qualitative study to understand concerns and supportive care needs of this novel survivor population... Conclusions: Longer term survivors of mNSCLC report significant physical, psychological and functional concerns and unmet needs. Self-management strategies for chronic toxicities, professional psychological services to manage FCP and scan-related anxiety, and tailored information regarding work and financial planning may mitigate these concerns. Future work should examine these issues in a larger population. READ ARTICLE

Journal of Clinical Oncology DOI:10.1200/JCO.2020.38.15_suppl.e24185

Authors: Julia Elizabeth Lai-Kwon, Sarah Heynemann, Jacinthe Flore, Mary Duffy, Renata Kokanovic, Michael Jefford

Imaging Features and Metastatic Patterns of Advanced ALK-Rearranged Non–Small Cell Lung Cancer

"ALK rearrangements are an established targetable oncogenic driver in non–small cell lung cancer (NSCLC). The goal of this study was to determine the imaging features of the primary tumor and metastatic patterns in advanced ALK-rearranged (ALK+) NSCLC that may be different from those in EGFR-mutant (EGFR+) or EGFR/ALK wild-type (EGFR−/ALK−) NSCLC. CONCLUSION. Advanced ALK+ NSCLC has primary tumor imaging features and patterns of metastasis that are different from those of EGFR+ or EGFR−/ALK− wild type NSCLC at the time of initial presentation. READ ARTICLE

American Journal of Roentgenology DOI:10.2214/AJR.19.21982

Authors: Dexter P. Mendoza, Jessica J. Lin, Marguerite M. Rooney, Tianqi Chen, Lecia V. Sequist, Alice T. Shaw, Subba R. Digumarthy"

Real-World OutcomesKirk SmithApril 1, 2020ALK, anaplastic lymphoma kinase, lung cancer, metastasis

Sequential EGFR mutation and ALK rearrangement in adenocarcinoma lung, with rare metastasis to bilateral breast, ovary and endometrium

With the advent of targeted therapies there was a paradigm shift in the treatment of metastatic adenocarcinoma of lung. Immuno-histopathology and molecular subtyping in metastatic adenocarcinoma lung have enabled personalized treatment for each patient. Oncogenic driver mutations in non-small cell lung cancer are commonly EGFR (Epidermal Growth Factor Receptor) gene mutation and ALK (Anaplastic Lymphoma Kinase) gene rearrangement, which are mutually exclusive. Almost 60–64% patients have oncogenic mutation, which are mutually exclusive. Here, we present a case with EGFR mutation and ALK gene rearrangement which was expressed sequentially and with metastasis to rarest sites bilateral breast, ovaries and endometrium. Even though presented with upfront metastatic disease, patient was treated with multiple lines of targeted agents, by which patient survived for 5 years with good quality of life. READ ARTICLE

Respiratory Medicine Case Reports DOI:10.1016/j.rmcr.2019.100954

Authors: V. R. Anjali, Rambha Pandey, Astha Srivastava, Madhu Rajeshwari, Durgatosh Pandey, M. C. Sharma